Triangle Coviracil Study Completion Funded Via $100 Mil. Equity Facility
Triangle Pharmaceuticals' $100 mil. equity facility appears to be sufficient to finance the company until it completes clinical development of the HIV nucleoside analogue Coviracil (emtricitabine).
You may also be interested in...
Revised black box labeling for Boehringer Ingelheim/Roxane antiretroviral Viramune (nevirapine) states that patients must receive liver monitoring during the first 12 weeks of therapy.
Triangle Pharmaceuticals could file an NDA for its anti-HIV product Coactinon (emivirine) by year-end under a $335 mil. co-promotion agreement with Abbott announced June 3.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011